United Kingdom

Draft Access

Reimbursed Care Access

TBD executive summary

Read Full Access Guide View Active Trials

Clinical Trials in United Kingdom

RecruitingPhase II

A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorder

Phase IIb randomised, double-blind trial (n=96) comparing two doses of psilocybin (25 mg vs 5 mg) plus psychological support; two doses given one month apart with outcomes over 33 weeks in adults with severe GAD.

Started: April 1, 2026
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: ISRCTN14487299

RecruitingPhase III

A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder (EMBRACE)

Phase III, quadruple-blind, randomised, placebo-controlled trial (n=330) of CYB003 (8 mg and 16 mg; two dosing sessions ~3 weeks apart) as adjunctive treatment for major depressive disorder.

Started: July 8, 2025
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT06793397

CompletedPhase I

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

This Phase I randomised, single-blind trial (n=20) will study the effects of multiple low doses of psilocybin (MLS101) on brain activity, safety, tolerability, and pharmacokinetics in healthy adult volunteers.

Started: July 1, 2025
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: NCT07050368

RecruitingPhase II

Ketamine for the treatment of depression with anorexia nervosa

This randomised, double-blind, placebo-controlled Phase II trial (n=60) will study the feasibility, safety, and acceptability of oral ketamine (60–180 mg, administered twice weekly) as a treatment for adults with long-standing anorexia nervosa and comorbid treatment-resistant depression.

Started: June 12, 2025
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: ISRCTN26462355

RecruitingPhase I

Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs (DIPP-RCFT)

Randomised controlled feasibility trial (n=40) comparing a 21-day meditation-based DIPP versus a music-based DIPP control, each followed by a supervised 25 mg psilocybin session at University College London.

Started: March 1, 2025
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: NCT06815653

CompletedPhase II

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

This Phase IIa, multi-centre, double-blind, randomised, placebo-controlled trial (n=60) will investigate the safety, tolerability, and efficacy of EMP-01 in adults with social anxiety disorder (SAD). Participants will be randomised 1:1 to receive two administrations of either 225 mg EMP-01 or placebo on Day 1 and Day 29, with the primary endpoint assessed at Day 43.

Started: March 1, 2025
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT06693609

United Kingdom

Reimbursed Care Access

Clinical Trials in United Kingdom

A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorder

A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder (EMBRACE)

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Ketamine for the treatment of depression with anorexia nervosa

Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs (DIPP-RCFT)

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

Research Events

Organizations8

Cambridge Psychedelic Research Group

Exeter Psychedelic Research Group

Imperial College London

King's College London

University College London

University of Cambridge

University of Greenwich

University of Manchester

Company

Product

Legal